Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

No effect of escitalopram versus placebo on brain-derived neurotrophic factor in healthy individuals: a randomised trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Markers of HPA-axis activity and nucleic acid damage from oxidation after electroconvulsive stimulations in rats

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Selective serotonin reuptake inhibitors are still harmful and ineffective. Responses to the comments by Hieronymus et al

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Differential plastic changes in synthesis and binding in the mouse somatostatin system after electroconvulsive stimulation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effects of erythropoietin on body composition and fat-glucose metabolism in patients with affective disorders

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Dynamic LED-light versus static LED-light for depressed inpatients: study protocol for a randomised clinical study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Sertraline in primary care: comments on the PANDA trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: Brain-derived neurotrophic factor (BDNF) seems to play an important role in the course of depression including the response to antidepressants in patients with depression. We aimed to study the effect of an antidepressant intervention on peripheral BDNF in healthy individuals with a family history of depression.

METHODS: We measured changes in BDNF messenger RNA (mRNA) expression and whole-blood BDNF levels in 80 healthy first-degree relatives of patients with depression randomly allocated to receive daily tablets of escitalopram 10 mg versus placebo for 4 weeks.

RESULTS: We found no statistically significant difference between the escitalopram and the placebo group in the change in BDNF mRNA expression and whole-blood BDNF levels. Post hoc analyses showed a statistically significant negative correlation between plasma escitalopram concentration and change in whole-blood BDNF levels in the escitalopram-treated group.

CONCLUSION: The results of this randomised trial suggest that escitalopram 10 mg has no effect on peripheral BDNF levels in healthy individuals.

OriginalsprogEngelsk
TidsskriftActa Neuropsychiatrica
Vol/bind2
Sider (fra-til)101-9
Antal sider9
ISSN1601-5215
DOI
StatusUdgivet - 2016

ID: 45806621